Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson's disease patients

Levodopa-carbidopa intestinal gel (LCIG) is delivered continuously via intrajejunal percutaneous gastrostomy tube. To examine long-term safety, efficacy and quality of life of LCIG in an open-label extension study. Patients received 52 weeks of open-label LCIG treatment following a 12-week double-bl...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of Parkinson's disease Ročník 5; číslo 1; s. 165
Hlavní autoři:	Slevin, John T, Fernandez, Hubert H, Zadikoff, Cindy, Hall, Coleen, Eaton, Susan, Dubow, Jordan, Chatamra, Krai, Benesh, Janet
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands 01.01.2015
Témata:	Age Factors Aged Antiparkinson Agents - therapeutic use Carbidopa - therapeutic use Double-Blind Method Drug Delivery Systems Female Gels - therapeutic use Humans Levodopa - therapeutic use Longitudinal Studies Male Middle Aged Parkinson Disease - drug therapy Severity of Illness Index clinical trial levodopa-carbidopa intestinal gel Parkinson's disease percutaneous endoscopic gastrostomy motor fluctuations
ISSN:	1877-718X, 1877-718X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!